Cellebrite DI Ltd.
NASDAQ:CLBTSoftware - Infrastructure
-$0.05 today
- Market cap
- $2.68B
- Beta
- 1.17
- P/E (TTM)
- 42.6
- EPS (TTM)
- $0.29
Volume 3.48M
Average 2.08M
CLBT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Cellebrite DI Ltd.NASDAQ: CLBT
Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026
Capital expenditures growth accelerates
Q3 FY2026 capital expenditures of $4.78M (cash outflow) rose 44.0% year over year, ahead of the +9.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 55.9% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.
Context
- Capital expenditures amounted to 2.8% of revenue in FY2025, up 0.1 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +44.0% holds above the trailing-twelve-month pace of +9.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (13.23M) USD
- Year-over-year change
- -24.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.23M) | -24.7% |
| FY2024 | 2024-12-31 | (10.61M) | -34.0% |
| FY2023 | 2023-12-31 | (7.92M) | +12.8% |
| FY2022 | 2022-12-31 | (9.09M) | -12.0% |
| FY2021 | 2021-12-31 | (8.11M) | — |
Capital Expenditures vs competitors
How CLBT compares with its peers on the latest reported figures
- CLBT's LTM Sep 2026 capital expenditures of $14.85M is the 2nd largest of the 4 companies compared; the peer median is $5.27M.
- Its year-over-year change of +9.3% is the 2nd highest of 3, against a peer median of +23.5%.
- Capital expenditures amounts to 2.8% of revenue for CLBT, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $144.57M | +45.7% | +34.4% | 4.2% | |
| LTM Sep 2026 | $14.85M | +9.3% | +13.3% | 2.8% | |
| LTM Mar 2026 | $5.27M | +1.3% | -25.8% | 5.3% | |
| LTM Jun 2025 | $987K | — | -25.6% | 3.6% | |
| Peer median (excluding CLBT) | $5.27M | +23.5% | -25.6% | 4.2% | |
Competitors are the stored peer set for CLBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 71.4M | 120.81M | (81.1M) | (283.01M) | 78.33M |
| Depreciation & Amortization | 7.01M | 9.19M | 10.01M | 10.61M | 11.87M |
| Deferred Income Tax | (1.64M) | (2.39M) | 5.13M | (4.02M) | 75K |
| Stock-Based Compensation | 6.48M | 13.71M | 19M | 30.58M | 0 |
| Change in Working Capital | 20.68M | (2.82M) | 38.52M | 42.05M | 42.02M |
| Accounts Receivables | (1.96M) | (12.89M) | 2.27M | (5.83M) | (15.78M) |
| Inventory | (1.8M) | (3.68M) | 243K | 982K | 1.63M |
| Accounts Payables | 4.24M | (5.47M) | 3.69M | 2.76M | 9.19M |
| Other Working Capital | 20.2M | 19.22M | 32.31M | 44.14M | 46.98M |
| Other Non-Cash Items | (67.87M) | (117.92M) | 110.51M | 335.96M | 36.67M |
| Operating Cash Flow | 36.05M | 20.58M | 102.06M | 132.17M | 168.96M |
| Capital Expenditures | (8.11M) | (9.09M) | (7.92M) | (10.61M) | (13.23M) |
| Acquisitions (Net) | (20M) | 0 | 0 | (2.75M) | (147.46M) |
| Purchases of Investments | (21M) | (165.36M) | (144.32M) | (334.79M) | (321.23M) |
| Sales of Investments | 94.34M | 83.22M | 129.7M | 198.67M | 212.8M |
| Other Investing Activities | (3M) | (2.19M) | (2.69M) | (2.04M) | 861K |
| Investing Cash Flow | 45.23M | (91.23M) | (22.54M) | (149.47M) | (268.25M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 4.59M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 25.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (100M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 31.6M | 13.97M | 21.77M | 20.65M | 0 |
| Financing Cash Flow | (68.4M) | 13.97M | 21.77M | 20.65M | 29.64M |
| Effect of Forex Changes | (754K) | (1.64M) | 589K | (1.21M) | 2.45M |
| Net Change in Cash | 12.13M | (58.33M) | 101.87M | 2.14M | (67.2M) |
| Free Cash Flow | 27.94M | 11.49M | 94.14M | 121.56M | 155.73M |
Cellebrite DI Ltd.
NASDAQ:CLBT
Intrinsic Alpha fair value
Locked
Current Price
$10.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.